Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Long-Term Deferred Tax (2022 - 2025)

Kiniksa Pharmaceuticals International's Long-Term Deferred Tax history spans 4 years, with the latest figure at $198.1 million for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax fell 6.16% year-over-year to $198.1 million; the TTM value through Dec 2025 reached $198.1 million, down 6.16%, while the annual FY2025 figure was $198.1 million, 6.16% down from the prior year.
  • Long-Term Deferred Tax reached $198.1 million in Q4 2025 per KNSA's latest filing, down from $201.3 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $219.3 million in Q4 2023 to a low of $184.4 million in Q1 2023.
  • Average Long-Term Deferred Tax over 4 years is $201.7 million, with a median of $204.1 million recorded in 2023.
  • Peak YoY movement for Long-Term Deferred Tax: rose 18.22% in 2023, then fell 6.16% in 2025.
  • A 4-year view of Long-Term Deferred Tax shows it stood at $185.5 million in 2022, then increased by 18.22% to $219.3 million in 2023, then dropped by 3.71% to $211.2 million in 2024, then dropped by 6.16% to $198.1 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Long-Term Deferred Tax are $198.1 million (Q4 2025), $201.3 million (Q3 2025), and $205.5 million (Q2 2025).